



## Clinical trial results: Acute Effects of Benzbromaron on the pulmonary circulation Summary

EudraCT number	2015-000709-38
Trial protocol	AT
Global end of trial date	23 June 2016

### Results information

Result version number	v1 (current)
This version publication date	28 March 2019
First version publication date	28 March 2019

### Trial information

#### Trial identification

Sponsor protocol code	BBR
-----------------------	-----

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02790450
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Medical University of Graz
Sponsor organisation address	AUenbruggerplatz 20, Graz, Austria, 8036
Public contact	Department for Pulmonology, Medical University of Graz, 43 31638512183, gabor.kovacs@klinikum-graz.at
Scientific contact	Department for Pulmonology, Medical University of Graz, 43 31638512183, gabor.kovacs@klinikum-graz.at

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	23 June 2016
Is this the analysis of the primary completion data?	Yes
Primary completion date	23 June 2016
Global end of trial reached?	Yes
Global end of trial date	23 June 2016
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

---

Main objective of the trial:

to assess the change of pulmonary vascular resistance 2 hours after the application of 200mg benzbromaron

Protection of trial subjects:

only patients with clinically indicated right heart catheterization were included in order to minimise study-related complications

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 August 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

---

Country: Number of subjects enrolled	Austria: 10
Worldwide total number of subjects	10
EEA total number of subjects	10

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	4
From 65 to 84 years	6
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Patients of the Medical University of Graz with known pulmonary arterial hypertension and clinically indicated right heart catheterization were recruited between November 2015 and June 2016.

### Pre-assignment

Screening details:

We identified n=10 patients with known PAH and clinically indicated right heart catheterization in the recruitment period. N=2 patients were excluded - one due to elevated pulmonary arterial wedge pressure (>15mmHg) and another due to elevated serum bilirubin (>1.6 mg/dl) and impaired GFR. N=8 patients completed the study.

### Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

<b>Arm title</b>	all patients
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	Benzbromaron
Investigational medicinal product code	PR1
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

200 mg single dose

<b>Number of subjects in period 1</b>	all patients
Started	10
Completed	8
Not completed	2
elevated bilirubin and impaired GFR at baseline	1
Adverse event, non-fatal	1

## Baseline characteristics

### Reporting groups

Reporting group title

Overall trial

Reporting group description: -

Reporting group values	Overall trial	Total	
Number of subjects	10	10	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	4	4	
From 65-84 years	6	6	
85 years and over	0	0	
Gender categorical			
Units: Subjects			
Female	9	9	
Male	1	1	

## End points

### End points reporting groups

Reporting group title	all patients
Reporting group description: -	

### Primary: change in pulmonary vascular resistance 120 minutes after benzbromarone application as compared to baseline

End point title	change in pulmonary vascular resistance 120 minutes after benzbromarone application as compared to baseline <sup>[1]</sup>
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

120 minutes

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This is a pilot study. An explorative analysis for the primary and secondary end-points has been performed. This compared the pulmonary vascular resistance (primary end-point) and other values at baseline and 120 minutes after administration of Benzbromaron.

End point values	all patients			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: pulmonary vascular resistance				
number (not applicable)	8			

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

120 minutes

Adverse event reporting additional description:

N=2 patients did not complete the study. Both of them were excluded from the study before the administration of Benzbromaron, so they did not receive the single dose of the study drug. The reasons for discontinuation were 1. non-serious adverse event (elevated pulmonary arterial wedge pressure) and 2. impaired renal and hepatic function.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	18
--------------------	----

### Reporting groups

Reporting group title	all patients
-----------------------	--------------

Reporting group description: -

Serious adverse events	all patients		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 8 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 1 %

Non-serious adverse events	all patients		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1 / 8 (12.50%)		
Cardiac disorders			
increased pulmonary arterial wedge pressure			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported